Clofarabine

Generic Name: Clofarabine

Brand Names: Clolar, Evoltra

Drug Type: Small Molecule

Chemical Formula: C_₁₀H_₁₁ClFN_₅O_₃

CAS Number: 123318-82-1

Unique Ingredient Identifier: 762RDY0Y2H

Background: Clofarabine is a purine nucleoside antimetabolite that is being studied in the treatment of cancer. It is marketed as Clolar in the U.S. and Canada, or Evoltra in Europe, Australia, and New Zealand. Clofarabine is used in paediatrics to treat a type of leukaemia called relapsed or refractory acute lymphoblastic leukaemia (ALL), only after at least two other ...

Indication: For the treatment of pediatric patients 1 to 21 years old with relapsed or refractory acute lymphocytic (lymphoblastic) leukemia after at least two prior regimens. It is designated as an orphan drug by the FDA for this use.

Associated Conditions: Refractory Acute Lymphoblastic Leukemia (ALL), Refractory Acute Myeloid Leukemia (AML), Relapsed Acute Lymphoblastic Leukemia (ALL), Refractory Langerhans cell histiocytosis

Associated Therapies: -

Clinical Trials

Clofarabine Bone Marrow Cytoreduction

Phase 2

Completed

Conditions: Leukemia

Interventions: Drug: Clofarabine

First Posted Date: 2008-07-29

Last Posted Date: 2014-03-18

Lead Sponsor: University of Chicago

Target Recruit Count: 29

Registration Number: NCT00724009

Locations: 🇺🇸
The University of Chicago hospitals, Chicago, Illinois, United States

Low-dose Oral Clofarabine for the Treatment of IPSS INT-1, INT-2 or HIGH Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia

Phase 1

Terminated

Conditions: Cancer
Chronic Myelomonocytic Leukemia

Interventions: Drug: Clofarabine

First Posted Date: 2008-07-02

Last Posted Date: 2017-06-01

Lead Sponsor: University of Utah

Target Recruit Count: 11

Registration Number: NCT00708721

Locations: 🇺🇸
Huntsman Cancer Institute, Salt Lake City, Utah, United States

Clofarabine Plus Cytarabine Versus Conventional Induction Therapy And A Study Of NK Cell Transplantation In Newly Diagnosed Acute Myeloid Leukemia

Phase 3

Completed

Conditions: Acute Myeloid Leukemia

Interventions: Drug: Cytarabine
Drug: Daunorubicin
Drug: Clofarabine
Drug: Etoposide
Device: CliniMACS

First Posted Date: 2008-06-24

Last Posted Date: 2021-08-10

Lead Sponsor: St. Jude Children's Research Hospital

Target Recruit Count: 324

Registration Number: NCT00703820

Locations: 🇺🇸
University of Chicago, Chicago, Illinois, United States
🇺🇸
Stanford University Medical Center, Palo Alto, California, United States
🇺🇸
St. Jude Children's Research Hospital, Memphis, Tennessee, United States

and more 5 locations

Clofarabine for Myelodysplastic Syndrome (MDS) Patients Who Failed Vidaza Treatment (tx)

Phase 2

Terminated

Conditions: Myelodysplastic Syndromes

Interventions: Drug: Clofarabine

First Posted Date: 2008-06-18

Last Posted Date: 2013-03-15

Lead Sponsor: Texas Oncology Cancer Center

Target Recruit Count: 10

Registration Number: NCT00700011

Locations: 🇺🇸
Texas Oncology Cancer Center, Amarillo, Texas, United States

Pilot Study of Haploidentical Natural Killer Cell Infusions for Poor Prognosis Non-AML Hematologic Malignancies

Phase 1

Completed

Conditions: Acute Lymphoblastic Leukemia
Chronic Myelogenous Leukemia
Juvenile Myelomonocytic Leukemia
Myelodysplastic Syndrome
Non-Hodgkin's Lymphoma

Interventions: Other: NK Cell Infusion
Biological: Immunotherapy
Device: Miltenyi Biotec CliniMACS device
Drug: Interleukin-2 (IL-2)
Drug: Clofarabine
Drug: Cyclophosphamide
Drug: Etoposide

First Posted Date: 2008-06-16

Last Posted Date: 2013-07-16

Lead Sponsor: St. Jude Children's Research Hospital

Target Recruit Count: 48

Registration Number: NCT00697671

Locations: 🇺🇸
St. Jude Children's Research Hospital, Memphis, Tennessee, United States

Reduced Intensity Conditioning With Clofarabine, Antithymocyte Globulin (ATG), Total Lymphoid Irradiation (TLI) Followed by Allogeneic Stem Cell Transplant

Phase 1

Completed

Conditions: Acute Lymphocytic Leukemia
Relapsed/Refractory Chronic Lymphocytic Leukemia
Acute Myeloid Leukemia
Hodgkins Disease
Myelodysplastic Syndrome
Relapsed/Refractory Non Hodgkin's Lymphoma
Relapsed Refractory Multiple Myeloma

Interventions: Drug: Antithymocyte Globulin
Drug: Clofarabine

First Posted Date: 2008-06-16

Last Posted Date: 2023-11-28

Lead Sponsor: Beth Israel Deaconess Medical Center

Target Recruit Count: 29

Registration Number: NCT00697684

Locations: 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States

Clofarabine and Rituximab in Treating Patients With Relapsed Non-Hodgkin Lymphoma

Phase 1

Terminated

Conditions: Lymphoma

Interventions: Biological: rituximab
Drug: clofarabine
Genetic: DNA methylation analysis
Genetic: gene expression analysis
Genetic: microarray analysis
Genetic: polymerase chain reaction
Other: high performance liquid chromatography
Other: laboratory biomarker analysis

First Posted Date: 2008-06-05

Last Posted Date: 2019-11-27

Lead Sponsor: OHSU Knight Cancer Institute

Target Recruit Count: 2

Registration Number: NCT00691652

Locations: 🇺🇸
Knight Cancer Institute at Oregon Health and Science University, Portland, Oregon, United States

Oral Clofarabine for Relapsed/Refractory Non-Hodgkin Lymphoma

Phase 1

Completed

Conditions: Lymphoplasmacytic Lymphoma
Angioimmunoblastic T-cell Lymphoma
Follicular Lymphoma
Low Grade B-cell Lymphoma, Not Otherwise Specified
Anaplastic Large-cell Lymphoma
Marginal Zone Lymphoma
Mantle Cell Lymphoma
Small Lymphocytic Lymphoma
Peripheral T-cell Lymphoma
Diffuse Large B-cell Lymphoma

Interventions: Drug: Clofarabine

First Posted Date: 2008-03-26

Last Posted Date: 2023-03-15

Lead Sponsor: Massachusetts General Hospital

Target Recruit Count: 50

Registration Number: NCT00644189

Locations: 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

Clofarabine and High-Dose Melphalan Followed by Donor Stem Cell Transplant in Patients With Acute Myeloid Leukemia, Acute Lymphocytic Leukemia, or Myelodysplastic Syndromes

Phase 1

Completed

Conditions: Leukemia
Myelodysplastic Syndromes

First Posted Date: 2008-03-21

Last Posted Date: 2023-06-15

Lead Sponsor: City of Hope Medical Center

Target Recruit Count: 20

Registration Number: NCT00641030

Locations: 🇺🇸
City of Hope Comprehensive Cancer Center, Duarte, California, United States

Antithymocyte Globulin, Clofarabine, and Rituximab in Treating Patients After an Unsuccessful Stem Cell Transplant

Phase 2

Terminated

Conditions: Cancer

Interventions: Biological: anti-thymocyte globulin
Biological: rituximab
Drug: clofarabine
Procedure: stem cell transplantation

First Posted Date: 2008-02-18

Last Posted Date: 2017-12-28

Lead Sponsor: Masonic Cancer Center, University of Minnesota

Target Recruit Count: 12

Registration Number: NCT00617929

Locations: 🇺🇸
Masonic Cancer Center at University of Minnesota, Minneapolis, Minnesota, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy